Archive for Stock Market News – Page 2

SoftBank & CEMEX lead the Weekly top Gainers/Losers this week

By IFCMarkets

Top Gainers – The World Market

1. SoftBank Corp – quotations of the Japanese telecommunications and Internet company.

2. Tronox Ltd – quotations of the American manufacturer of titanium and titanium dioxide.

market sentiment ratio long short positions

 Top Losers – The World Market

1. CEMEX – quotations of the American manufacturer of cement and building materials.

2. Mitsubishi Chemical Holdings Corp – quotations of the Japanese chemical company.

market sentiment ratio long short positions

 Top Gainers – Foreign Exchange Market (Forex)

1. USDZAR, EURZAR – the growth of these charts indicates the weakening of the South African rand against the US dollar and the euro.

2. USDPLN, USDNOK – the growth of these charts indicates the strengthening of the US dollar against the Polish Zloty and the Norwegian Krone.

market sentiment ratio long short positions

 Top Losers – Foreign Exchange Market (Forex)

1. AUDUSD, NZDUSD – the decrease in this chart means the strengthening the US dollar against the Australian and New Zealand dollars.

2. EURUSD, EURHKD – the decrease in this chart means the weakening of the euro against the US and Hong Kong dollars.

market sentiment ratio long short positions

Market Analysis provided by IFCMarkets

Note:
This overview has an informative and tutorial character and is published for free. All the data, included in the overview, are received from public sources, recognized as more or less reliable. Moreover, there is no guarantee that the indicated information is full and precise. Overviews are not updated. The whole information in each overview, including opinion, indicators, charts and anything else, is provided only for familiarization purposes and is not financial advice or а recommendation. The whole text and its any part, as well as the charts cannot be considered as an offer to make a deal with any asset. IFC Markets and its employees under any circumstances are not liable for any action taken by someone else during or after reading the overview.

2019 Starting to Shine But is it a Long Con for Investors?

By TheTechnicalTraders.com

An odd thing happened at the beginning of 2019 for the markets – price levels across almost all sectors were deeply depressed as a result of the October through December 2018 price correction.  We’re noticing that almost all sectors of the SP500 were relatively deeply depressed just before Christmas 2018 and the recent price rally has set up an interesting psychological phenomenon – a self-propelling bullish mantra for US Stocks.

Yes, 2018 ended with a drop – almost a CRASH.  Yet, 2019 is starting off on a terror rally that is beginning to lay the grounds for a very dramatic Q1 and possibly Q2 recovery for many in the managed and passive funds.  Remember the news in early January 2019?  Hedge funds losing 12~22% or more for the 2018 end of year returns?  Remember the feeling that these firms just couldn’t find any means of success when almost the entire 2018 year was mired in deep price rotations and sideways trading?

So far, 2019 is starting out vastly different but I have to wonder if the mega players/market movers of the world planned for a very week 2018. Maybe the big plan here is to make the first half of 2019 looks incredibly strong like the bull market is still in full force to convince new money to enter while they secretly unload shares before the bear market takes hold?

If you follow our research, you’ll recall our September 17, 2018 market prediction that an “Ultimate Low” would setup after the US November 2018 elections prompting an incredible upside price rally.  You can read out exact wording here.  We followed that article with an Elections Cycle research article showing how US election cycles tend to create FEAR in the markets, read it here.

Lastly, we followed up these research pieces with our Global Market research suggesting that perceptions are changing across the planet in terms of what is an acceptable risk and where capital will likely flow in the future. If you have not read this yet be sure to do so.

We believe the psychological results of the US markets pushing very strong Q1 and Q2 returns from a very deep price origination point could drive this global capital shift to target the US markets much more quickly than we expected.  If the US markets continue to push higher with fairly narrow volatility going forward, we believe global capital will rush into the US market and undervalued technology, healthcare, basic materials and other sectors chasing the opportunity for the +5 to +8% returns on the back of a potentially strong US Dollar.  It may seem odd that this type of capital shift could even take place right now, but we believe this renewed boost of foreign capital into the US stock markets has already started and will play a big roll in a final run higher in the overall US equities market for a few months.

This Weekly NQ chart shows our Predictive Fibonacci price modeling system and suggests that volatility has already begun to narrow.  You can see the CYAN “Immediate Upside Target” level that is our current price target and the first level where resistance may be found.  Beyond that level, we enter the upward sloping YELLOW price channel from 2018 that suggests price may attempt a rally up towards the $8400 level.  You can also see our Fibonacci Projected Targets labeled “Ultimate Upside Projected Targets”.  These levels are created by an adaptive learning price modeling system where volatility, price range, price rotation, and an active learning Fibonacci modeling tool are suggesting “could be” the ultimate upside objectives.  Imagine the NQ starting 2019 near $6400 and ending it near $9200 (+43%) or $9600 (+50%) for the year??  It would be incredible and it is a possibility.

The reality is, it does not matter what the markets do, go up or down from there. Technical analysis will keep the odds in our favor for us to follow the market closely and generate strong annual gains. No one truly knows which way the markets are headed next. Personally, I feel stocks will struggle to make new highs before rolling over to start a bear market, but our ADL adaptive statical system says we should be prepared of the possibility of a 50% rally.

So who/what is correct? It does not matter, either way, we will make money, but I a bear market does start then long-term investments will need to be moved to cash or inverse investments at that time.

Take a minute to consider how the global markets will react to uncertainty and rotation while remembering that the US stock market and economy are very unique from the rest of the world.  The US economy seems to operate beyond the limitations of many other foreign markets and could turn into a safe-harbor for global capital throughout the next 2~5+ years.  Time will tell.

Please take a minute to visit TheTechnicalTraders.com to learn how we can help you find and execute better trade in 2019 and stay ahead of these market moves.

Chris Vermeulen

By TheTechnicalTraders.com

 

The weak statistics increase recession risks

By IFCMarkets

Weak macroeconomic data affected US stocks and the dollar rate

Retail sales in the US for December 2018 decreased by 1.2% compared with November. This is their maximum fall in the last 9 years. Negative has been added by a decline in the producer price index in January and the increase of unemployment over the week. A number of investors have a fear that such statistics indicate a slowdown in the growth of the American economy. Coca-Cola and American International Group (AIG) reporting for the 4th quarter of 2018 was released yesterday. It turned out to be weak, which caused a drop in shares of the manufacturer of soft drinks and the insurance company by 7.6%. Market participants lowered their growth forecast for the companies of S&P 500 index to 16.2% in the 4th quarter. Today at 16:00 CET consumer confidence indicator from the University of Michigan will be published in the United States. Yesterday The ICE US Dollar index slightly decreased , as weak macroeconomic statistics reduces the likelihood of a Fed rate hike.

The euro depreciation has not yet received further development

Eurozone GDP for the 4th quarter of last year grew by 1.2% in annual terms, as expected. This is worse than the 3rd quarter, in which it rose by 1.6%. At the same time, Germany’s GDP showed zero quarterly growth and was weaker than preliminary forecasts. This increases the risk of recession in the EU. Now EURUSD is below the psychological level of 1.13. Many European stock indexes updated 3-month highs yesterday due to the good quarterly reporting by Airbus manufacturer, the British pharmaceutical company AstraZeneca, food and beverage producer Nestle and Commerzbank. At the end of the day, European stock indices still fell due to weak macroeconomic statistics. Today Eurozone trade balance for December will be published. Investors will focus on ongoing US-China trade negotiations.

Japanese Nikkei ended up lower along with other global stock indices

At the end of the week, the Nikkei was still in positive rate by 2.8%. Weak macroeconomic data in the United States reduces the likelihood of further growth of the Fed rate. Due tothis, the yield of government bonds of the United States and other countries may decrease. Accordingly, this negatively affected the quotes of Japanese financial companies Dai-ichi Life Holdings (-4.7%),T&D Holdings (-3.5%) and Mitsubishi UFJ Financial Group (-1.4%).USDJPY, Australian and New Zealand dollars strengthened in anticipation of the US-China trade negotiations outcome.

Quotations of US Natural Gas are near the minimum since June 2016

The cost of liquefied natural gas (LNG) in Southeast Asia has fallen to a minimum in 17 years due to the high competition of suppliers. In addition, China has slightly reduced its LNG purchases, waiting the start of Russian gas supplies by the Power of Siberia pipeline. All this reduces the demand for NATGAS. However, there is positive news. According to U.S. Energy Information Administration, gas reserves in the United States decreased by 4.1% over the week and amounted to 53.3 billion cubic meters. This is due to a cold snaps in a number of US states where gas is used for heating.

Market Overview IFC Markets chart

Market Analysis provided by IFCMarkets

Note:
This overview has an informative and tutorial character and is published for free. All the data, included in the overview, are received from public sources, recognized as more or less reliable. Moreover, there is no guarantee that the indicated information is full and precise. Overviews are not updated. The whole information in each overview, including opinion, indicators, charts and anything else, is provided only for familiarization purposes and is not financial advice or а recommendation. The whole text and its any part, as well as the charts cannot be considered as an offer to make a deal with any asset. IFC Markets and its employees under any circumstances are not liable for any action taken by someone else during or after reading the overview.

Biotech Identifies Antibody Drug Candidates to Target Toxic Protein Implicated in Parkinson’s Disease

By The Life Science Report

Source: Streetwise Reports   02/13/2019

The Canadian company continues seeking partners to leverage its discovery and development platform.

ProMIS Neurosciences Inc. (PMN:TSX; ARFXF:OTCQB) announced in a news release it identified several monoclonal antibody drug candidates for Parkinson’s disease. The candidates precisely target only the toxic forms of the protein alpha-synuclein, considered to be a root cause of Parkinson’s disease.

“We used our proprietary discovery platform to generate several antibody drug candidates for Parkinson’s disease that precisely target only the toxic forms of alpha-synuclein,” stated Dr. James Kupiec, ProMIS’ chief medical officer. “Selectivity represents the essential feature of a successful antibody therapy, for it is critical that treatment not hinder normal forms of alpha-synuclein that play an important functional role in the brain. In preclinical studies, ProMIS antibody candidates showed a high degree of selectivity for only the toxic forms of alpha-synuclein in a side-by-side comparison with other alpha-synuclein targeting antibodies that are currently in development.”

Preclinical in vitro studies demonstrated these candidates block neurotoxicity and the spreading of toxic alpha-synuclein while binding only to the toxic forms of the protein, the company noted.

ProMIS stated it has “created a novel, proprietary method for discovering and developing antibodies that can uniquely and precisely target these specific toxic forms.”

“Competitive differentiation of ProMIS antibodies is key to ongoing partnering discussions with large pharmaceutical companies,” the company stated.

Sign up for our FREE newsletter at: www.streetwisereports.com/get-news

Disclosure:
1) Doresa Banning compiled this article for Streetwise Reports LLC and provides services to Streetwise reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: ProMIS Neurosciences. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports’ terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases. As of the date of this article, officers and/or employees of Streetwise Reports LLC (including members of their household) own securities of ProMIS Neurosciences, a company mentioned in this article.

( Companies Mentioned: PMN:TSX; ARFXF:OTCQB,
)

Bringing Advanced Technology to the Cannabis Space

By The Life Science Report

Source: Streetwise Reports   02/13/2019

This cannabis technology company brings artificial intelligence, blockchain and cryptocurrency to the global medical cannabis marketplace to help patients make informed decisions and drive medical cannabis sales.

Global Cannabis Applications Corp. (APP:CSE; FUAPF:OTCQB; 2FA:FSA) is a developer of innovative data technologies for the cannabis industry. The Canada-based company began as a mobile applications developer and transformed to apply its knowledge and experience to the emerging medical cannabis industry.

In early 2017 the company underwent a name change, management change and a strategic change to pursue opportunities in the medical cannabis space. “Global Cannabis Applications (GCAC) was born to address the void of patient data and product information in the medical cannabis industry,” stated Bradley Moore, Global Cannabis CEO and director. “With the recent legalization of recreational cannabis in Canada and medical cannabis throughout the U.S. at the state level, the industry has become an economic force.”

Global Cannabis recently launched its first sales program to retail cannabis dispensaries in California, Utah and Arizona. “Along with partner agreements in Latin America, GCAC is poised to begin generating significant revenues,” Moore said.

New Strategy, New Markets, New Mission

Initially management focused on patient applications with the company launching patient-centric mobile apps in 2017 and early 2018 to support this effort. As the company developed and launched these apps, “it became obvious that there was a greater opportunity to focus on patient and product data and information that could benefit all stakeholders of the cannabis industry, including patients, medical professionals, dispensaries and licensed producers. This was an opportunity to broaden the reach of the Citizen Green technology beyond the patient and generate significant opportunities,” Moore told Streetwise Reports.

“We set our sights on using its advanced technology to build applications that would create the largest patient outcomes and product data repository in the cannabis industry,” Moore explained.

Citizen Green Technologies

Starting with a proprietary database of over 10 years of medical cannabis field research, Moore set out to build a data solution that would ultimately connect patients, dispensaries, medical professionals and licensed producers. To complete this task, “we assembled an impressive team of uniquely qualified individuals that brought together five core technologies into one single data solution: mobile applications, artificial intelligence, smart databases, blockchain and digital reward tokens. The platform motivates and retains customers, increases dispensary revenues, drives product conversations and transactions, and perhaps most importantly improves medical outcomes for medical cannabis patients,” he stated.

A common term of the cannabis industry lexicon is “seed to sale,” which tracks the journey of the cannabis plant or product from when it is planted to when it is eventually sold as a medical product. Moore told Streetwise Reports, “the Citizen Green Community closes the seed to sale loop by tracking patient experience after the product is sold, truly bringing the process full circle from ‘seed to sale to seed.’ By closing the loop, not only does it answer questions like what strains are working, but more importantly it also maps the user treatment experience to determine future strain and product development.”

A Solution for Medical Cannabis Sellers

The Citizen Green Community offers retail dispensaries three main components to improve customer loyalty, retention and spend, with the goal of improving patients’ health and wellness.

1. Prescriptii Patient-Care Solution

This patient-care solution is an integrated retail and patient solution for both in store and online uses, and a connected mobile application. Prescriptii generates cannabis efficacy-based product recommendations for patients and tracks the treatment through the prescribing timeframe. “By capturing these anonymous data insights, the information can then be used by the dispensary to increase revenue per patient and optimize business operations from marketing to inventory management. Data insights are also the product of choice to be bought and sold on the Citizen Green MarketPlace,” Moore explained.

2. The Citizen Green Onward Rewards

Onward Rewards is a loyalty program designed to improve customer loyalty to a single retail dispensary and is powered by the Citizen Green Coin (CGC) digital reward token, or cryptocurrency. Moore explained, “The innovative CGCs are the loyalty currency, like points, that patients can earn through participation on the Prescriptii Patient-Care mobile app and can be redeemed for discounts on products. Retail dispensaries use CGCs to gain and increase customer retention, drive product sales and build the repository of data insights. CGCs are purchased from the company at US$0.10 per coin.”

3. Citizen Green MarketPlace

The data insights captured by individual dispensaries using the Prescriptii Patient-Care Solution have value, so GCAC created a marketplace where registered organizations could buy, sell and trade this information. Using the CGC as community currency, dispensaries can buy information and data from other non-competing dispensaries. For example, a Chilean dispensary could buy data from a U.S. dispensary to jump start its business, or to improve a marketing campaign for patient retention or acquisition. “The GCCs earned by the U.S. dispensary have real value and can be used for programs in their own loyalty programs,” Moore explained. “The ability for dispensaries to earn CGCs by selling anonymous patient data inputs means that the business cost for the Onward Rewards program is much lower than typical reward programs and could even pay for itself. As global data insights grow and are shared across the community, so do members’ business revenues.”

Multiple Levels of Revenue

GCAC is generating revenue by helping medical cannabis retail dispensaries grow their business using the Prescriptii Patient-Care Solution:

  • Dispensaries pay a monthly fee for access to the system depending on the number of patients they service,
  • Loyalty coins are purchased from GCAC as required based on individual dispensary needs,
  • Fees are charged for transactions taking place in the Citizen Green MarketPlace.

Due to the scalability of the Citizen Green Community, there is no limit to the number of global retail dispensaries registered on the system. In Q4 2018, GCAC launched a significant sales push into the United States to over 3,000 medical cannabis dispensaries across California, Arizona and Utah. “Owners of medical cannabis dispensaries are invited to visit the company’s citizengreen.io website to learn about the smart technology driven Citizen Green Community and to register for the patient-care solution,” Moore relayed.

GCAC is also working with partners to open new countries and languages, and develop new modules. In December, the company announced a partnership with Grassroots SpA to develop a Spanish version of Prescriptii Patient Care Solution and develop and release new online doctor scheduling and e-commerce modules for the local medical cannabis community.

The Value of Big Data

As the network of retail dispensaries builds, so does the database and so does the value of the database, explained Moore. “Through the advanced technologies previously mentioned, important market and data insights can be mined from the database. This valuable information will attract other industry stakeholders beyond retail dispensaries, including licensed producers, scientists, and medical professionals to join the Community, acquire CGCs and transact in the Citizen Green Marketplace. More members mean more transactions using more CGCs resulting in transactional revenue for the company and a greater overall value of GCAC.”

Future Initiatives with a Scalable Platform

GCAC has developed market-ready applications and is starting to generate revenue. “The Citizen Green Community was designed to be dynamic, scalable and easily translatable into other languages. Expansion into Latin America is a significant step for the company as it marks the second language that will be used for the Citizen Green Community. One can only think that German, French and other European languages are next to be embraced by the Citizen Green Community, and due to the nature of the blockchain and crypto economics of the Citizen Green Community, there is no limit to the number of medical cannabis partners that can join, suggesting significant upside potential to generate revenue. With little or no real competition, the future looks very bright,” Moore stated.

“As monthly revenues from partnerships and dispensaries using the Prescriptii Patient-Care Solution, Onwards Rewards program and the Citizen Green Marketplace increase, so does the value of the company’s proprietary database, and so should the share price,” he added.

GCAC trades on the Canadian Stock Exchange under the symbol APP and on the OCTPK with the symbol FUAPF. There are currently 92.5 million APP shares outstanding, and shares sit at around CA$0.10.

Sign up for our FREE newsletter at: www.streetwisereports.com/get-news

Disclosure:
1) Patrice Fusillo compiled this article for Streetwise Reports LLC and provides services to Streetwise reports as an employee. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: Global Cannabis Applications Corp. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports’ terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases. As of the date of this article, officers and/or employees of Streetwise Reports LLC (including members of their household) own securities of Global Cannabis Applications Corp., a company mentioned in this article.

( Companies Mentioned: APP:CSE; FUAPF:OTCQB; 2FA:FSA,
)

Report Highlights Biopharma’s Breakthroughs on Treatment of Life-Threatening Pediatric Liver Diseases

By The Life Science Report

Source: Streetwise Reports   02/13/2019

Analyst expects “transformational year” for company with a phase 3 trial underway.

In a Feb. 6 research report, ROTH Capital Partners analyst Yasmeen Rahimi highlighted three major developments in Albireo Pharma Inc.’s (ALBO:NASDAQ) efforts to produce and commercialize novel treatments for rare and life-threatening pediatric liver diseases that don’t have an approved pharmacologic treatment option.

Based on these developments, Rahimi anticipated that 2019’s first half will set the stage for “a transformational year” for Albireo and estimated a price target for the clinical-stage biopharmaceutical company of $86 and a projection of sales of more than $1.2 billion in both the United States and the European Union.

In her report, Rahimi said that 2019 “started off with a bang” for Albireo because the FDA granted in January an orphan drug for biliary atresia designation to the company’s main asset: A4250.

The FDA’s Orphan Drug Designation Program provides orphan status to drugs and biologics intended for the safe and effective treatment, diagnosis or prevention of rare diseases or disorders, according to the agency’s website.

Just a month before, Albireo’s A4250 received in Europe a designation similar to the FDA’s orphan status, added the report.

A4250 is an ileal bile acid transporter (IBAT) inhibitor. Albireo is developing it for the treatment of progressive familial intrahepatic cholestasis (PFIC), a rare and life-threatening liver disease with no approved pharmacologic treatment option. The drug is in a clinical testing phase.

Roth Capital Partners recently held talks with management of Albireo to closely discuss what 2019 has in store with respect to its A4250 development.

A4250’s clinical tests

In her report, Rahimi first underlined the rapid enrollment at the A4250’s current clinical trial program. The A4250 is conducting a phase 3 trial program. The program consists of a 24-week study on clinical sites of 60 pediatric patients.

Albireo is currently running over 30 clinical sites to test the A4250. Rahimi anticipated that all 35 to 45 guided clinical sites should be up and running by next month. The first results of the trial program are slated for readout during the first half of the year, added the report.

“Any way you dice the multiple scenarios, we think A4250 bile acid reduction in PFIC positions ALBO as a winner,” she wrote. She recalled that the previous clinical study showed a 71% bile acid reduction when compared to patients that took a placebo instead of A4250.

The report also forecasted that bile acid reductions in clinical studies of A4250 in Europe could lead to an approval of the drug in the European Medical Association (EMA) and the creation of a 4,000 to 5,000 market of patients that suffer from PFIC.

That approval, Rahimi added, could influence the FDA’s decisions on A4250.

A4250’s second indication

Second, Rahimi highlighted that Albireo is also planning to disclose a second pediatric liver indication for A4250 during the first half of this year.

In her report, she explained that “discussions with the FDA are ongoing.”

“We could see either biliary atresia or alagille syndrome, both ALBO orphan drug designations, chosen,” she wrote.

Biliary atresia is a rare gastrointestinal disorder characterized by the destruction or absence of all or a portion of the bile duct that lies outside the liver, according to the National Organization for Rare Disorders’ website.

Alagille syndrome is a genetic disorder that can affect the liver, heart and other parts of the body, according to the US National Library of Medicine’s website.

Elobixibat

Third, Albireo also plans to start early this year phase 2 of a study design on elobixibat, another inhibitor of the IBAT and the company’s second leading asset.

Albireo’s elobixibat has completed a successful phase 3 trial in Japan for the treatment of chronic constipation.

Valuation

Rahimi’s arrives at a price target for Albireo of $86. The valuation took into consideration three assumptions. The first was a price of $28 per share driven by a possible 2020 launch of A4250 for PFIC patients and peak sales of $593 million in the United States. The second assumption was a price of $39 per share driven by a possible launch of the experimental drug in the European Union (EU) in 2020 and peak sales of $693 million in that market. The third was a price of $19 per share driven by last year’s launch of elobixibat in Japan and peak sales of $196 million in that market.

Rahimi also arrived to a projection of sales of A4250 in both the United States and the European Union amounting $1.222 billion based on another three assumptions. The first one was that there are approximately 3,200 to 5,000 persons suffering from PFIC in both the United States and the EU. Secondly, that a launch of A4250 in 2020 for 2% of PFIC patients would grow to a 65% penetration in both the United States and the EU. In her third assumption, Rahimi modeled a $325,000 annual price for A4250 in the United Stated with a gross-to-net adjustment of 15%, a model lowered to a $243,000 annual price in the EU based on the lower pricing in other drugs prescribed for rare diseases.

Then, Rahimi projected her model to 2028 with a discount rate of 9% and acknowledges that clinical, regulatory and reimbursement risks may impede shares from achieving the slated price target.

According to the report, the primary clinical risk of her Albireo valuation is both a failure of the current phase 3 clinical study of A4250 and meaningful time delays in the availably of the study’s results.

Rahimi also acknowledged that the “long-term safety profile for A4250 has yet to be determined” because the previous phase 2 clinical study was based “on safety, tolerability, and efficacy over a maximum of four week dosing period.”

In contrast, the current phase 3 clinical testing of A4250 “is likely to test dosing periods of up to three months and will be accompanied by a long-term extension study, which is crucial since it is intended as life-long therapy.”

The main regulatory risks, explained Rahimi, is that “there a no definite regulatory pathways for PFIC therapy development since no treatments exist.” “With that said, ALBO is actively working with the FDA and EMA to establish acceptable surrogate endpoints, for approval in PFIC,” she clarified.

Rahimi, on the other hand, estimated that the high pricing pressure debate in the biotech space may lead to “significant reimbursement challenges, including increased coverage restrictions, coverage denials, or shifting costs to patients.”

Finally, and according to the report, Albireo reported last September cash and cash equivalents amounting $173.6 million.

Sign up for our FREE newsletter at: www.streetwisereports.com/get-news

Disclosure:
1) Mario Santana compiled this article for Streetwise Reports LLC and provides services to Streetwise reports as an independent contractor. He or members of his household own securities of the following companies mentioned in the article: None. He or members of his household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports’ terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.

Disclosures from ROTH Capital Partners, Albireo Pharma Inc., Flash Note, February 6, 2019

Regulation Analyst Certification (“Reg AC”): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

ROTH makes a market in shares of Albireo Pharma, Inc. and as such, buys and sells from customers on a principal basis.

ROTH Capital Partners, LLC expects to receive or intends to seek compensation for investment banking or other business relationships with the covered companies mentioned in this report in the next three months.

( Companies Mentioned: ALBO:NASDAQ,
)

Clinical Movement Expected in 2019 on Pharma Firm’s ‘Gene Therapy Promise’

By The Life Science Report

Source: Streetwise Reports   02/13/2019

A number of data readouts are expected in the coming months, which could derisk and accelerate development programs, according to an H.C. Wainwright & Co. report.

In a Feb. 8 research note, H.C. Wainwright analyst Andrew Fein wrote that Axovant Sciences Ltd. (AXON:NYSE) will likely clinically advance its gene therapy pipeline quickly.

Evidence of this, noted Fein, is the “strong execution” the company displayed over the past year, bolstering the pipeline, speeding up development timelines and recruiting top gene therapy experts. These efforts have been part of the company rebuild and shift into the gene therapy space.

Second, Fein highlighted, a steady flow of trial results is expected over the next few months. Specifically, initial data from AXO-Lenti-PD are anticipated in Q1/19, initial results from AXO-Lenti-PD are expected in March 2019 and initial findings from AXO-AAV-GM1 should read out in H2/19. These data releases can derisk those clinical programs.

“AXO-Lenti-PD is moving forward,” Fein indicated, and could do so on an accelerated development path by leveraging the data set from ProSavin, a predecessor gene therapy product. “For AXO-Lenti-PD, we believe that the scientific rationale is strong by delivering aromatic L-amino acid decarboxylase into the putamen of patients with Parkinson’s disease, and this approach has been supported by the clinical data from both ProSavin and VY-AADC thus far.”

Further, Fein added, the FDA indicated that Axovant may consider ProSavin results as part of one AXO-Lenti-PD development program, and it agreed with the company’s manufacturing and quality control plans.

As for Axovant’s financial standing, it had $84.9 million in cash and cash equivalents at year-end 2018.

H.C. Wainwright has a Buy rating and a $7 per share price target on Axovant, whose current share price is around $1.24.

Sign up for our FREE newsletter at: www.streetwisereports.com/get-news

Disclosure:
1) Doresa Banning compiled this article for Streetwise Reports LLC and provides services to Streetwise reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports’ terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.

Disclosures from H.C. Wainwright & Co., Axovant Sciences Ltd., Earnings Update, February 8, 2019

I, Andrew S. Fein, Li Wang Watsek and Alicia Yin, Ph.D., certify that 1) all of the views expressed in this report accurately reflect my personal views about any and all subject securities or issuers discussed; and 2) no part of my compensation was, is, or will be directly or indirectly related to the specific recommendation or views expressed in this research report; and 3) neither myself nor any members of my household is an officer, director or advisory board member of these companies.

Investment Banking Services include, but are not limited to, acting as a manager/co-manager in the underwriting or placement of securities, acting as financial advisor, and/or providing corporate finance or capital markets-related services to a company or one of its affiliates or subsidiaries within the past 12 months.

None of the research analysts or the research analyst’s household has a financial interest in the securities of Axovant Sciences Ltd., Neurocrine Biosciences, Inc. and Voyager Therapeutics, Inc. (including, without limitation, any option, right, warrant, future, long or short position).

As of January 31, 2019 neither the Firm nor its affiliates beneficially own 1% or more of any class of common equity securities of Axovant Sciences Ltd., Neurocrine Biosciences, Inc. and Voyager Therapeutics, Inc.

Neither the research analyst nor the Firm has any material conflict of interest in of which the research analyst knows or has reason to know at the time of publication of this research report.

The research analyst principally responsible for preparation of the report does not receive compensation that is based upon any specific investment banking services or transaction but is compensated based on factors including total revenue and profitability of the Firm, a substantial portion of which is derived from investment banking services.

The Firm or its affiliates did not receive compensation from Neurocrine Biosciences, Inc. and Voyager Therapeutics, Inc. for investment banking services within twelve months before, but will seek compensation from the companies mentioned in this report for investment banking services within three months following publication of the research report.

The Firm or its affiliates did receive compensation from Axovant Sciences Ltd. for investment banking services within twelve months before, and will seek compensation from the companies mentioned in this report for investment banking services within three months following publication of the research report.

H.C. Wainwright & Co., LLC managed or co-managed a public offering of securities for Axovant Sciences Ltd. during the past 12 months.

The Firm does not make a market in Axovant Sciences Ltd., Neurocrine Biosciences, Inc. and Voyager Therapeutics, Inc. as of the date of this research report.

( Companies Mentioned: AXON:NYSE,
)

US-China trade negotiations affect on global markets

By IFCMarkets

US stocks rose due to pending resolution of US-China trade deal

US Treasury Secretary Stephen Mnuchin said he was pleased with the trade negotiations. Inflation in the United States in January was 1.6% in annual terms, which is the minimum increase since June 2017. Core inflation remained at 2.2% year to year for the third consecutive month. Such stability eliminates the likelihood of a Fed rate hike at the next meeting on March 20. Nevertheless the ICE US Dollar Index gained on Wednesday and updated the 3-month high. Investors believe that the Chinese authorities may make some concessions in a trade dispute with the United States. The reporting season of US companies for the 4th quarter of 2018 is close to the end. Market participants believe that the total profit of S&P 500 now it will gain 16.6%, but will decrease by 0.3% in the first quarter of 2019. It limits the potential growth of quotations. Yesterday, after the end of trading, a positive quarterly report was published by the computer company Cisco Systems Inc., so futures on US stock indexes predictably will growth during today’s opening. Today at 14:30 CET the weekly data on the labor market will be announced in USA based on producer prices for January and retail sales for December.

The EUR/USD rate again fell below the 1.13 key support level

Industrial production in the Eurozone for December decreased by 4.2% in annual terms, which is noticeably worse than preliminary forecasts. The reduction in the production of fixed assets in industry accelerated to -5.5% year-on-year, compared with -4.4% in November. All this confirms the forecast of the European Commission about the slowdown in the growth of the Eurozone’s GDP to 1.3% in the current year compared to 1.9% in 2018. In addition to weak statistics, the negative impact on the EURUSD rate had political problems in the EU. The Spanish Parliament refused to approve the state budget for 2019. However it did not prevent the growth of European stock indices. This was facilitated by good corporate reporting for the 4th quarter of 2018. Market participants expect 3% growth of the total profit of European companies from the STOXX 600 index list. British stock index FTSE 100 updated 4-month high due to a fall in inflation in January to a 2-year low. Today Eurozone GDP for the 4th quarter will be published.

Japanese stock index Nikkei continued gaining for the 4th day in a row

Japanese exporting companies quotations strengthening contributes to the weakening of the yen. USDJPY also gained the 4th day in a row and has already updated the 7-week maximum. Honda Motor shares gained 1.3% and Advantest Corp 1.6%. New Zealand and Australian dollar got additional impetus to strengthen due to the publication of Chinese macroeconomic data. China is the main trading partner of these countries. In January, Chinese exports and trade surplus significantly exceeded forecasts.

Quotations of Brent significantly lose and updated a maximum of 2019

The oil prices increase is due to the optimism of market participants about the possible successful outcome of the US-China trade negotiations. In this case, the world economy may receive an additional impetus to development due to the cessation of trade wars. China reported an increase in oil imports in January of this year to 10.03 million barrels per day (bvd). This is 4.8% more than in January 2018. Chinese oil imports exceed the psychological level of 10 million USD for the third month in a row. IEA agency expects an increase in global consumption during current year by 1.4 million bvd, which implies the stability of demand.

Market Overview IFC Markets chart

Market Analysis provided by IFCMarkets

Note:
This overview has an informative and tutorial character and is published for free. All the data, included in the overview, are received from public sources, recognized as more or less reliable. Moreover, there is no guarantee that the indicated information is full and precise. Overviews are not updated. The whole information in each overview, including opinion, indicators, charts and anything else, is provided only for familiarization purposes and is not financial advice or а recommendation. The whole text and its any part, as well as the charts cannot be considered as an offer to make a deal with any asset. IFC Markets and its employees under any circumstances are not liable for any action taken by someone else during or after reading the overview.

S&P500 Explodes To Best January Since 1987. What’s Next?

By Admiral Markets

The S&P 500 stock market index (SP500) has posted its best January performance in more than thirty years. However, with 2018 reporting the worst December since 1931 – and the worst year since the financial crisis – many people believe the January 2019 rally was simply a rebound from massively oversold levels.

Is this rally short lived, or can it last throughout the year? Let’s look at the statistical, fundamental, and technical evidence…

The January Barometer: 86.8% Chance Of A Bullish Year?

Did you know there is a saying on trading floors which states: “As the S&P goes in January, so goes the year”?

Chart showing the best January bump in over 30 years

Source: Admiral Markets MT5 Supreme Edition, SP500, Weekly – Data range: from September 20, 2015, to February 8, 2019, accessed on February 8, 2019, at 3:23pm GMT. – Please note: Past performance is not a reliable indicator of future results.

The January Barometer statistical indicator was first created by Yale Hirsch in 1972. The long term record is impressive with an 86.8% accuracy rate. In fact, there have only been nine major errors in sixty-eight years, most of these occurring in secular bear markets.

Needless to say, this doesn’t mean the market will move upwards in a straight line for the rest of the year – if it will at all – but it does provide an interesting statistical bias or, as traders would say, ‘an edge’. While some market professionals are sceptical of the barometer, Hirsch says it makes sense, “because that’s when Wall Street expectations are reset for the year… [and] when big investors and pension funds put money to work for the new year, or not”.

Hirsch also established another statistical measure known as the ‘first five days’ phenomenon. Let’s look into this index as well:

First Five Days Barometer: 82% Chance Of A Bullish Year?

This statistical indicator is based on an analysis of the first five trading days of the year. If it ends positive, then history shows there is a stronger bias for the year to end positive, as well. The trend is so strong that since 1950, when a given year’s first five trading days ended positive, the S&P 500 index has likewise ended the year positive 82% of the time – with an average gain of 13.3%.

Yet even more positively, in pre-presidential election years, this indicator performs even better. In the last seventeen pre-presidential election years, twelve of them followed the direction of the ‘first five days’ phenomenon. With 2019 being a pre-presidential election year, it can be an extra edge in a trader’s arsenal.

While the statistical side shows a higher bias towards the S&P 500 index ending positive this year, there are fundamental headwinds that could still make the year a wild ride and perhaps move outcomes even lower.

S&P 500 Fundamentals: The Fed, China & Trade

One of the many reasons 2018 was the worst year for the S&P 500 since the financial recession is because of the US Federal Reserve increasing interest rates. The uncertainty on the impact of increasing rates on the economy spooked many investors. However, the federal funds futures market is currently not pricing in any rate hike this year – helping to give stocks another potential boost.

Another issue that has caused concern for investors is the ongoing tension surrounding trade talks between Washington and Beijing. While US president Donald Trump’s and Chinese premier Xi Jinping’s teams are negotiating a trade deal, no headway has yet been made. Even though this issue continues to weigh on sentiment, an end to the trade war could be a big boost to global stock markets.

However, the fundamental scenarios have not stopped Wall Street analysts having a $3,000 median target for the S&P 500 by December 2019, providing a good amount of possibilities for uplift from current levels:

Wall Street's general outlook

Source: CNBC

It is worthwhile noting that some investment banks, such as Morgan Stanley, believe that stocks are in a rolling ‘bear market’, with a 50% chance of a small earnings recession this year and a low target of $2,750 for December 2019.

So what does the SP500 CFD technical chart tell us about this time frame?

Long Term Trading View: SP500 Index CFD

Long term SP500 CFD index chart

Source: Admiral Markets MT5 Supreme Edition, SP500, Weekly – Data range: from January 30, 2011, to February 8, 2019, accessed on February 8, 2019, at 4:14pm GMT. – Please note: Past performance is not a reliable indicator of future results.

In the SP500 CFD weekly chart shown above, it is clear to see the long term picture remains bullish. While the sharp drop in 2018 is evident, the market has since bounced higher off the 200 weekly moving average (the green line).

The last time the market bounced off this moving average was the week of February 7, 2016. After this period, the market made a series of swings, with higher high and higher low cycles trending for the proceeding several years.

Longer term traders will be looking for the market to repeat similar characteristics, either to keep them in their long positions, or to initiate new positions in line with the overall trend. As the S&P 500 is an index of the largest five-hundred stocks listed on the New York Stock Exchange, some advanced traders may use the index as an indicator of overall sentiment to aid in their decision to trade individual stocks and shares.

Short Term Trading View: SP500 CFD

Short term SP500 CFD index chart

Source: Admiral Markets MT5 Supreme Edition, SP500, Daily – Data range: from April 19, 2018, to February 8, 2019, accessed on February 8, 2019, at 4:22pm GMT. – Please note: Past performance is not a reliable indicator of future results.

The above chart shows daily price action bars of the SP500 CFD. The blue line represents the 20 daily moving average. Shorter term traders may use this as a short term trend filter and look for long positions when price is above the line, and short positions when price falls below it. This could help to stay with the ‘momentum’ of the market.

Price action-based strategies could aid in identifying possible turning points within this momentum. For example, an inside bar is a popular price action pattern that represents a pause in the market. It is shown by a daily bar’s high and low price range trading within the high and low price range of its previous bar. The theory is that this pause in the market is like a ‘breather’ before the market breaks out and continues in its trend.

On January 29, 2019, an inside bar formed on the chart of the SP500 CFD. Traders could have entered a buy order at the high of the inside bar, $2,652, with a stop loss at the low of the inside bar, $2,628.

With a 10 lot position size, this would result in a $240 loss if the entry and then stop loss was triggered. However, in this instance, the index continued to move higher. Trailing the stop loss beneath each daily bar’s low would have resulted in an exit on February 7 at $2,723. This would have resulted in an approximate profit of $710.

Conclusion

While most analysts are seemingly bullish on the S&P 500 index for the end of the year, the market may see a lot of up and down volatility before then. Using a combination of both short term and long term trading strategies could prove to be effective for those happy with the risk. How will you be trading this year?

Download MetaTrader 5 and start trading today!

The given data provides additional information regarding all analysis, estimates, prognosis, forecasts or other similar assessments or information (hereinafter “Analysis”) published on the website of Admiral Markets. Before making any investment decisions please pay close attention to the following:

  1. The analysis is published for informative purposes only and are in no way to be construed as investment advice or recommendation.
  2. Any investment decision is made by each client alone whereas Admiral Markets shall not be responsible for any loss or damage arising from any such decision, whether or not based on the Analysis.
  3. Each of the Analysis is prepared by an independent analyst (Jitan Solanki, Freelance Contributor) based on personal estimations.
  4. To ensure that the interests of the clients would be protected and objectivity of the Analysis would not be damaged Admiral Markets has established relevant internal procedures for prevention and management of conflicts of interest.
  5. Whilst every reasonable effort is taken to ensure that all sources of the Analysis are reliable and that all information is presented, as much as possible, in an understandable, timely, precise and complete manner, Admiral Markets does not guarantee the accuracy or completeness of any information contained within the Analysis. The presented figures refer that refer to any past performance is not a reliable indicator of future results.
  6. The contents of the Analysis should not be construed as an express or implied promise, guarantee or implication by Admiral Markets that the client shall profit from the strategies therein or that losses in connection therewith may or shall be limited.
  7. Any kind of previous or modeled performance of financial instruments indicated within the Publication should not be construed as an express or implied promise, guarantee or implication by Admiral Markets for any future performance. The value of the financial instrument may both increase and decrease and the preservation of the asset value is not guaranteed.
  8. The projections included in the Analysis may be subject to additional fees, taxes or other charges, depending on the subject of the Publication. The price list applicable to the services provided by Admiral Markets is publicly available from the website of Admiral Markets.

Leveraged products (including contracts for difference) are speculative in nature and may result in losses or profit. Before you start trading, you should make sure that you understand all the risks.

Article by Admiral Markets

Source: S&P500 Explodes To Best January Since 1987. What’s Next?


Admiral Markets is a leading online provider, offering trading with Forex and CFDs on stocks, indices, precious metals and energy.

 

Marijuana Stocks Ready for Another Massive Rally?

By TheTechnicalTraders.com

Our research team has been actively discussing the potential that the entire Marijuana stock sector could be setting up for another upside price rally.  Since the bottom set up in the US stock market near December 24, 2018, many of the cannabis-related stocks and ETFs have seen incredible upside recoveries (of 25% or more).  We believe the current setup in MJ, the Alternative Harvest ETF, is indicative of a new bullish momentum breakout.

The upside potential for this move is likely 12~25% or more over a short span of time.  Watching MJ move from $34 to $39 over the next few weeks could result in a 14%+ move where a breakout of $39 to the upside could see MJ retesting recent highs near $45 (a +32% upside move).

One aspect of this market sector to consider is the recent talk of nationalizing legal US cannabis in the US as well as the expected gains in state sales from legalizing the industry.  We’ve all read about how some of the largest drink and tobacco producers in the world are investing heavily into this blossoming sector in preparation to secure market share when the dust settles.  The entire Marijuana market sector could be a boom cycle, similar to Cryptos in 2016~2017, over the next 12~24+ months in the USA. Canada recently legalized its use which could help open the door for other territories to make it legal.

MJ has room to run to the upside and our initial projected targets for this upside move are just below $38.  If our longer-term analysis is correct and the US major stock market indexes continue to rally, we believe MJ could attempt to retest recent highs near $45 over the next 30~60+ days.

These types of opportunities don’t happen very often. Fledgling industries with strong interest drive investors to make speculative plays while driving prices higher and higher in most cases.  Play this one smart and look to take profits above +8% on no less than half of your initial trade, then let the rest of your position ride out the run.  If we are correct in our targets, $41~44 should be the next upside target before resistance is found.

Another interesting way to look for interest in any sector is to look at the Google Trends for the search term popularity for a particular asset class or similar related phrases and Bitcoin is the perfect example.

 

 

Marijuana Stocks Searches

As you can see in the graph below Google trends is shows a steady increase of interest for “Marijuana Stocks” stocks.

We should warn you that this is also a capitulation and contrarian indicator once it breaks the 80-100 level. When search demand spikes and everyone is interested in these stocks that is when they top. So, we do expect a run-up in price, but after that price could go up in smoke as this is somewhat of a bong bubble in the asset class.

 

If you want to join a group of professional traders, researchers, and friends, then visit TheTechnicalTraders.com to learn how we can help you find and execute better trades.  Some of our recent winners are GDXJ 10.5%, ROKU 8.1%, two other open positions with 15.4%, and 4% as we wait for new a couple high momentum trades to mature.

We believe 2019 and 2020 will be incredible years for skilled traders and we are executing at the highest level we can to assist our member’s profit from our trades with us. In fact, we are about to launch our newest trading solution for ourselves and members that is unparalleled anywhere else.

Chris Vermeulen
Technical Traders Ltd.